Illumina, Inc. (NASDAQ:ILMN) Shares Sold by ProShare Advisors LLC

ProShare Advisors LLC cut its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 88.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 19,018 shares of the life sciences company's stock after selling 146,984 shares during the period. ProShare Advisors LLC's holdings in Illumina were worth $2,541,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Golden State Wealth Management LLC purchased a new stake in Illumina in the fourth quarter valued at approximately $32,000. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in shares of Illumina in the 4th quarter valued at $45,000. Assetmark Inc. increased its stake in shares of Illumina by 954.8% in the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock worth $44,000 after acquiring an additional 296 shares during the period. Lee Danner & Bass Inc. purchased a new position in shares of Illumina during the fourth quarter worth $48,000. Finally, V Square Quantitative Management LLC lifted its position in Illumina by 50.6% during the fourth quarter. V Square Quantitative Management LLC now owns 393 shares of the life sciences company's stock valued at $52,000 after purchasing an additional 132 shares during the period. Hedge funds and other institutional investors own 89.42% of the company's stock.

Illumina Trading Down 0.2%

NASDAQ ILMN traded down $0.17 on Monday, reaching $80.37. 1,536,714 shares of the company were exchanged, compared to its average volume of 2,326,484. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The business's fifty day moving average price is $78.14 and its 200 day moving average price is $108.39. The stock has a market capitalization of $12.72 billion, a P/E ratio of -10.46, a price-to-earnings-growth ratio of 1.60 and a beta of 1.35. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.96 by $0.01. Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. The firm had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.03 billion. During the same quarter in the prior year, the firm posted $0.98 earnings per share. Illumina's quarterly revenue was down 1.4% on a year-over-year basis. Analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current year.

Insider Transactions at Illumina

In other Illumina news, CFO Ankur Dhingra acquired 6,100 shares of the business's stock in a transaction that occurred on Monday, May 12th. The stock was purchased at an average cost of $81.21 per share, with a total value of $495,381.00. Following the transaction, the chief financial officer now owns 24,906 shares of the company's stock, valued at $2,022,616.26. This trade represents a 32.44% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 2.60% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on ILMN. Citigroup cut their price target on Illumina from $90.00 to $85.00 and set a "neutral" rating on the stock in a research report on Monday, April 7th. Guggenheim lowered their target price on Illumina from $122.00 to $114.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Morgan Stanley reduced their price target on Illumina from $136.00 to $100.00 and set an "equal weight" rating for the company in a research report on Monday, May 12th. Robert W. Baird lowered their price objective on Illumina from $127.00 to $90.00 and set a "neutral" rating on the stock in a research report on Wednesday, March 5th. Finally, Piper Sandler dropped their price objective on shares of Illumina from $190.00 to $185.00 and set an "overweight" rating on the stock in a research note on Thursday, May 15th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $128.15.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.